Form 4: Dyne Therapeutics CMO Receives Performance-Based Stock Options Tied to $20 Share Price Target

Dyne Therapeutics' Chief Medical Officer, Douglas Kerr, was granted 65,110 performance-based stock options with an exercise price of $9.33, contingent on the stock reaching $20.00 within three years.

Summary

• Douglas Kerr, Chief Medical Officer of Dyne Therapeutics, Inc. (DYN), was granted 65,110 stock options on July 16, 2025.
• The exercise price for these options is $9.33 per share.
• The options are scheduled to expire on July 15, 2035.
• Vesting occurs over three years, with 50% vesting 18 months after the grant date and the remainder in equal quarterly installments thereafter.
• The options are only exercisable if the average closing price of Dyne's common stock reaches or exceeds $20.00 per share over a 20-consecutive trading day period within three years of the grant date, or if a Change in Control occurs within that period at a price per share of $20.00 or more.

Sentiment

Score: 7

Explanation: The grant of performance-based stock options to a key executive (CMO) is generally positive as it aligns management incentives with shareholder value creation, contingent on a significant stock price increase. However, the future-dated grant and the high performance hurdle introduce a degree of uncertainty regarding the ultimate benefit to the executive and potential future dilution.

Positives

• The grant of performance-based stock options aligns the Chief Medical Officer's incentives directly with shareholder value creation, as the options only become exercisable if the stock price significantly increases to $20.00 or more.
• The long expiration date of July 15, 2035, provides a substantial window for the performance conditions to be met and for the options to be exercised.

Negatives

• The options are not exercisable unless a significant stock price target of $20.00 is met, meaning the options could potentially never be exercised if the performance condition is not achieved within the three-year performance period.

Risks

• The primary risk is that the performance condition (stock price reaching $20.00 per share over a 20-day period within three years) may not be met, rendering the options unexercisable despite vesting.

Future Outlook

The future exercisability of the granted stock options is contingent on Dyne Therapeutics' common stock achieving an average closing price of $20.00 or more over a 20-consecutive trading day period within three years from the grant date (July 16, 2025), or a qualifying Change in Control event at or above that price within the same period. Vesting of the options is scheduled over three years, with 50% vesting 18 months after the grant date and the remainder quarterly thereafter.

Industry Context

This Form 4 filing details a specific executive compensation event within Dyne Therapeutics, a biotechnology company. Performance-based stock options are a common compensation tool in the biotech industry, aiming to incentivize executives to drive significant share price appreciation, often tied to clinical milestones or market valuation targets. The $20.00 performance hurdle suggests a significant growth expectation for the company's stock within the next three years, which is typical for a growth-oriented biotech firm.

Comparison to Industry Standards

• Performance-based equity awards, particularly those with specific stock price hurdles, are a common practice in the biotechnology and pharmaceutical sectors to align executive incentives with shareholder returns.
• For instance, companies like Moderna or BioNTech have historically used similar mechanisms to reward executives for achieving significant market capitalization milestones or successful drug development outcomes.
• The three-year performance period and the 20-day average closing price condition are standard structures for such awards, designed to ensure sustained performance rather than short-term fluctuations.
• The $20.00 target, relative to the $9.33 exercise price, represents a substantial required increase, indicating a strong belief in future growth potential, comparable to aggressive targets seen in high-growth biotech startups.

Stakeholder Impact

• Shareholders: Potential positive impact if the stock price reaches the $20.00 target, indicating significant value creation. Potential for future dilution if options are exercised.
• Employees: No direct impact mentioned for general employees, but the compensation structure for a key executive could set a precedent or reflect the company's overall compensation philosophy.
• Management: The Chief Medical Officer's compensation is now significantly tied to the company's stock performance, incentivizing efforts to increase share value.

Next Steps

• The stock options will begin their vesting schedule, with 50% vesting 18 months after July 16, 2025, and the remainder vesting quarterly thereafter.
• The company's common stock will need to achieve an average closing price of $20.00 or more over a 20-consecutive trading day period within three years from July 16, 2025, for the options to become exercisable.
• Alternatively, a Change in Control event at or above $20.00 per share within the three-year performance period could also trigger exercisability.

Key Dates

Keywords

Dyne Therapeutics, DYN, Stock Options, Performance-Based Compensation, SEC Form 4, Insider Trading, Executive Compensation, Biotechnology, Pharmaceuticals, Chief Medical Officer